Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,179 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF.
McMurray JJV, Jackson AM, Lam CSP, Redfield MM, Anand IS, Ge J, Lefkowitz MP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Rizkala AR, Sabarwal SV, Shah AM, Shah SJ, Shi VC, van Veldhuisen DJ, Zannad F, Zile MR, Cikes M, Goncalvesova E, Katova T, Kosztin A, Lelonek M, Sweitzer N, Vardeny O, Claggett B, Jhund PS, Solomon SD. McMurray JJV, et al. Among authors: van veldhuisen dj. Circulation. 2020 Feb 4;141(5):338-351. doi: 10.1161/CIRCULATIONAHA.119.044491. Epub 2019 Nov 17. Circulation. 2020. PMID: 31736337 Free article.
Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population.
Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans RO, Janssen WM, Grobbee DE, de Jong PE; Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Hillege HL, et al. Among authors: van gilst wh, van veldhuisen dj. Circulation. 2002 Oct 1;106(14):1777-82. doi: 10.1161/01.cir.0000031732.78052.81. Circulation. 2002. PMID: 12356629
Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL).
Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, Djian J, Drexler H, Feldman A, Kober L, Krum H, Liu P, Nieminen M, Tavazzi L, van Veldhuisen DJ, Waldenstrom A, Warren M, Westheim A, Zannad F, Fleming T. Mann DL, et al. Among authors: van veldhuisen dj. Circulation. 2004 Apr 6;109(13):1594-602. doi: 10.1161/01.CIR.0000124490.27666.B2. Epub 2004 Mar 15. Circulation. 2004. PMID: 15023878 Clinical Trial.
Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria.
Asselbergs FW, Diercks GF, Hillege HL, van Boven AJ, Janssen WM, Voors AA, de Zeeuw D, de Jong PE, van Veldhuisen DJ, van Gilst WH; Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators. Asselbergs FW, et al. Among authors: van gilst wh, van boven aj, van veldhuisen dj. Circulation. 2004 Nov 2;110(18):2809-16. doi: 10.1161/01.CIR.0000146378.65439.7A. Epub 2004 Oct 18. Circulation. 2004. PMID: 15492322 Clinical Trial.
Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS).
Teerlink JR, McMurray JJ, Bourge RC, Cleland JG, Cotter G, Jondeau G, Krum H, Metra M, O'Connor CM, Parker JD, Torre-Amione G, Van Veldhuisen DJ, Frey A, Rainisio M, Kobrin I; VERITAS Investigators. Teerlink JR, et al. Among authors: van veldhuisen dj. Am Heart J. 2005 Jul;150(1):46-53. doi: 10.1016/j.ahj.2005.04.035. Am Heart J. 2005. PMID: 16084150
Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III.
Willenheimer R, van Veldhuisen DJ, Silke B, Erdmann E, Follath F, Krum H, Ponikowski P, Skene A, van de Ven L, Verkenne P, Lechat P; CIBIS III Investigators. Willenheimer R, et al. Among authors: van de ven l, van veldhuisen dj. Circulation. 2005 Oct 18;112(16):2426-35. doi: 10.1161/CIRCULATIONAHA.105.582320. Epub 2005 Sep 4. Circulation. 2005. PMID: 16143696 Clinical Trial.
Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure.
van der Meer P, Lipsic E, Westenbrink BD, van de Wal RM, Schoemaker RG, Vellenga E, van Veldhuisen DJ, Voors AA, van Gilst WH. van der Meer P, et al. Among authors: van de wal rm, van gilst wh, van veldhuisen dj. Circulation. 2005 Sep 20;112(12):1743-7. doi: 10.1161/CIRCULATIONAHA.105.549121. Circulation. 2005. PMID: 16172283
Renal function as a predictor of outcome in a broad spectrum of patients with heart failure.
Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S, Granger CB, Michelson EL, Ostergren J, Cornel JH, de Zeeuw D, Pocock S, van Veldhuisen DJ; Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Investigators. Hillege HL, et al. Among authors: van veldhuisen dj. Circulation. 2006 Feb 7;113(5):671-8. doi: 10.1161/CIRCULATIONAHA.105.580506. Circulation. 2006. PMID: 16461840
Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction <or=30%.
Pitt B, Gheorghiade M, Zannad F, Anderson JL, van Veldhuisen DJ, Parkhomenko A, Corbalan R, Klug EQ, Mukherjee R, Solomon H; EPHESUS Investigators. Pitt B, et al. Among authors: van veldhuisen dj. Eur J Heart Fail. 2006 May;8(3):295-301. doi: 10.1016/j.ejheart.2005.11.008. Epub 2006 Feb 28. Eur J Heart Fail. 2006. PMID: 16504579 Free article. Clinical Trial.
1,179 results